Clinical Trial

Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer

Study acronym: PANDORA
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Phase III, single-center, randomized, double-blind, placebo-controlled, 2x2 cross- over study, assessing the efficacy of CBD in patients with early HR+ BC, presenting aromatase inhibitor-related musculoskeletal pain
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-16; most recent amendment 2025-11-24.
Trial Details
NCT Number NCT06787118
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, HR+ Breast Cancer, AI-related Musculoskeletal Pain
Enrollment 130 participants
Start Date 2025-12
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-12-02